Retina is a Marker for Cerebrovascular Heath

ConditionsCerebral Small Vessel Diseases Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy Cerebral Microbleeding Sporadic White Matter Disease

Trial statusRecruiting

Trial phasePhase 1, Phase 2

Trial typeInterventional

Biological sexAll

Age18+

SponsorMayo Clinic

About this trial

Cerebral small vessel disease (SVD), present in 80-94% of adults over age 65 years, increases the risk of stroke by 2-fold, and dementia by 2.3-fold. There is currently no treatment to slow SVD progression. This study aims to test whether impaired cerebral and retinal vasoreactivity may serve as biomarker for SVD progression, and to evaluate the safety and efficacy of cilostazol (antiplatelet agent with vasodilatory and anti-inflammatory properties) for the treatment of SVD.

Eligibility criteria

Qualifiers

Age ≥18 yo.

Diagnosis of CADASIL, sporadic WMD or lobar CMB and age-matched healthy controls (eg. patient's spouse or unrelated friends without SVD)

Disqualifiers

Age<18yo

Pregnant

Breast feeding

Unable to follow commands

Trial design

Treatments tested in this trial

Cilostazol

Treatment groups

100 Participants

are divided into 2 treatment groups

Sponsors and collaborators

Mayo Clinic

Lead sponsor

Source ClinicalTrials.gov